[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483448":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":182,"collaborators":10,"id":185,"slug":186,"hasResults":187,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":187,"sex":193,"minAge":194,"maxAge":195,"enrollmentInfo":196,"targetDuration":10,"studyType":199,"phases":10,"briefSummary":200,"conditions":201,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":212},{"fullName":5,"class":6},"424 General Military Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"single Zol group",null,"postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive a single zoledronate infusion (5mg) at 6 months after the last denosumab dose",[13],"Drug: Zoledronate or Alendronate",{"label":15,"type":10,"description":16,"interventionNames":17},"double Zol group","postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive two zoledronate infusions (5mg) at 6 and 12 months after the last denosumab dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"ALN group","postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive alendronate 70mg orally weekly for 12 months",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Zoledronate or Alendronate","infusion (for zoledronate) or oral digestion (for alendronate)",[19,15,9],[29],"Calcium and vitamin D supplementation",[31],{"name":32,"affiliation":33,"role":34},"Willem Lems, Prof","ECTS Clinical Action Group","PRINCIPAL_INVESTIGATOR",[36,42],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Athanasios D Anastasilakis, MD","CONTACT","2310381431","+30","a.anastasilakis@gmail.com",{"name":43,"role":38,"phone":10,"phoneExt":10,"email":44},"John Carey, MD","john.j.carey@universityofgalway.ie",[46,62,78,89,100,116,134,152,168],{"facility":47,"status":48,"city":49,"state":10,"zip":10,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Univ. Lille, CHU Lille","RECRUITING","Lille","France","FR",{"type":53,"coordinates":54},"Point",[55,56],3.05512,50.63391,{"lat":56,"lon":55},[59],{"name":60,"role":38,"phone":10,"phoneExt":10,"email":61},"Julien Paccou, Prof","Julien.PACCOU@chu-lille.fr",{"facility":63,"status":48,"city":64,"state":10,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"251 Hellenic Airforce and VA General Hospital","Athens","11525","Greece","GR",{"type":53,"coordinates":69},[70,71],23.72784,37.98376,{"lat":71,"lon":70},[74],{"name":75,"role":38,"phone":76,"phoneExt":10,"email":77},"Polyzois Makras, PhD","+30 2107463606","pmakras@gail.com",{"facility":79,"status":48,"city":64,"state":10,"zip":80,"country":66,"countryCode":67,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens","11527",{"type":53,"coordinates":82},[70,71],{"lat":71,"lon":70},[85],{"name":86,"role":38,"phone":87,"phoneExt":10,"email":88},"Maria P Yavropoulou, Consultant","+30 2132060800","myavropoulou@med.uoa.gr",{"facility":90,"status":48,"city":64,"state":10,"zip":91,"country":66,"countryCode":67,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},", KAT General Hospital","14561",{"type":53,"coordinates":93},[70,71],{"lat":71,"lon":70},[96],{"name":97,"role":38,"phone":98,"phoneExt":10,"email":99},"Symeon Tournis, PhD","+30 2132086000","stournis@med.uoa.gr",{"facility":5,"status":48,"city":101,"state":10,"zip":102,"country":66,"countryCode":67,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Thessaloniki","56429",{"type":53,"coordinates":104},[105,106],22.93493,40.64072,{"lat":106,"lon":105},[109,112],{"name":110,"role":38,"phone":111,"phoneExt":10,"email":41},"Athanasios D Anastasilakis, PhD","+302310381697",{"name":113,"role":38,"phone":114,"phoneExt":10,"email":115},"Stergios A Polyzos, PhD","+302310455780","stergios@endo.gr",{"facility":117,"status":118,"city":119,"state":10,"zip":10,"country":120,"countryCode":121,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico","NOT_YET_RECRUITING","Milan","Italy","IT",{"type":53,"coordinates":123},[124,125],9.18951,45.46427,{"lat":125,"lon":124},[128,131],{"name":129,"role":38,"phone":10,"phoneExt":10,"email":130},"Cristina Eller-Vainicher","eller.vainicher@gmail.com",{"name":132,"role":133,"phone":10,"phoneExt":10,"email":10},"Giorgia Grassi, MD","SUB_INVESTIGATOR",{"facility":135,"status":118,"city":136,"state":10,"zip":137,"country":120,"countryCode":121,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Campus Bio-Medico University","Roma","00128",{"type":53,"coordinates":139},[140,141],11.10642,44.99364,{"lat":141,"lon":140},[144,147,149,151],{"name":145,"role":38,"phone":10,"phoneExt":10,"email":146},"Andrea Palermo, Ass Prof","A.Palermo@unicampus.it",{"name":148,"role":38,"phone":10,"phoneExt":10,"email":10},"Gaia Tabacco, PhD",{"name":150,"role":133,"phone":10,"phoneExt":10,"email":10},"Anda Naciu, PhD",{"name":148,"role":133,"phone":10,"phoneExt":10,"email":10},{"facility":153,"status":118,"city":154,"state":10,"zip":155,"country":120,"countryCode":121,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Department of Medicine, Surgery and Neurosciences, University of Siena","Siena","53100",{"type":53,"coordinates":157},[158,159],11.33064,43.31822,{"lat":159,"lon":158},[162,165,167],{"name":163,"role":38,"phone":10,"phoneExt":10,"email":164},"Luigi Gennari, prof","gennari@unisi.it",{"name":166,"role":38,"phone":10,"phoneExt":10,"email":10},"Daniela Merlotti",{"name":166,"role":133,"phone":10,"phoneExt":10,"email":10},{"facility":169,"status":118,"city":170,"state":10,"zip":10,"country":120,"countryCode":121,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"University-Hospital S. Maria della Misericordia","Udine",{"type":53,"coordinates":172},[173,174],13.23715,46.0693,{"lat":174,"lon":173},[177,180],{"name":178,"role":38,"phone":10,"phoneExt":10,"email":179},"Fabio Vescini","fabio.vescini@asufc.sanita.fvg.it",{"name":181,"role":133,"phone":10,"phoneExt":10,"email":10},"Antonio Salcuni",{"type":34,"investigatorFullName":183,"investigatorTitle":184,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Athanasios D. Anastasilakis","Consultant of endocrinology; in charge of the Department of Metabolic Bone Diseases","100483448","single-or-repeat-zoledronate-versus-alendronate-following-denosumab-european-denosumab-effects-consolidation-study-100483448",false,"NCT05575167","Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","The Effectiveness of Single or Repeat Zoledronate Infusion Versus Oral Alendronate in Consolidating the Bone Accrual Achieved With Denosumab: a Study Organised by the European Calcified Tissue Society","EURODEC","Inclusion Criteria:\n\n• Postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia\n\nExclusion Criteria:\n\n* a bone disease other than postmenopausal osteoporosis\n* use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months before entering the study\n* creatinine clearance \\\u003C60 mL\u002Fmin\u002F1.73 m2\n* liver failure\n* any type of cancer\n* uncontrolled endocrine diseases\n* serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng\u002FmL (50 nmol\u002FL)","FEMALE","50 Years","85 Years",{"count":197,"type":198},125,"ESTIMATED","OBSERVATIONAL","A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab",[202],"Osteoporosis, Postmenopausal","2025-04-24",{"date":205,"type":206},"2025-04-27","ACTUAL",{"date":208,"type":206},"2023-11-28",{"date":210,"type":198},"2027-11",{"name":5,"class":6},9]